1 |
SIGMAR1
| [2] Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
2 |
ADORA1
| [7] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
3 |
ADORA1
| [7] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
4 |
ADORA2A
| [7] Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
5 |
ADORA2A
| [7] Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
6 |
ADRA2A
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| [4] 6 6, 65, 70, 78 |
7 |
ADRA2B
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| [4] 6 6, 65, 70, 78 |
8 |
ADRA2C
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| [4] 6 6, 65, 70, 78 |
9 |
CYP19A1
| [3] Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Ovarian steroidogenesis | D00960
D00960
|
Anastrozole
| [3] 78 78, 86, 193 |
10 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D03297
D03297
|
Mecasermin
| [6] 65 65, 78, 96, 168, 265, 299 |
11 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D05394
D05394
|
Pegvisomant
| [2] 78 78, 265 |
12 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D11193
D11193
|
Somavaratan
| [1] 78 78 |
13 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D11194
D11194
|
Somapacitan
| [2] 78 78, 195 |
14 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D11486
D11486
|
Lonapegsomatropin
| [1] 78 78 |
15 |
GHRHR
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D06655
D06655
|
Tesamorelin
| [2] 78 78, 265 |
16 |
GHRHR
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D08523
D08523
|
Somatorelin
| [2] 13 13, 78 |
17 |
GHSR
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10563
D10563
|
Macimorelin
| [1] 78 78 |
18 |
GLP1R
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D04121
D04121
|
Exenatide
| [6] 6 6, 17, 72, 78, 193, 233 |
19 |
GRIN1
| [18] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
20 |
GRIN2A
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
21 |
GRIN2B
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
22 |
GRIN2C
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
23 |
GRIN2D
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
24 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00088
D00088
|
Hydrocortisone
| [5] 78 78, 81, 83, 97, 299 |
25 |
IGF1R
| [29] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Oocyte meiosis, Autophagy - animal, Endocytosis, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Focal adhesion, Adherens junction, Signaling pathways regulating pluripotency of stem cells, Long-term depression, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Glioma, Prostate cancer, Melanoma, Breast cancer, Hepatocellular carcinoma | D03297
D03297
|
Mecasermin
| [6] 65 65, 78, 96, 168, 265, 299 |
26 |
AR
| [4] Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00075
D00075
|
Testosterone
| [8] 1 1, 2, 3, 13, 60, 76, 78, 113 |
27 |
MC2R
| [5] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome | D00284
D00284
|
Tetracosactide
| [5] 78 78, 83, 113, 145, 222 |
28 |
ACHE
| [2] Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D07869
D07869
|
Donepezil
| [9] 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
29 |
MTNR1A
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| [12] 6 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202 |
30 |
MTNR1B
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| [12] 6 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202 |
31 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D08623
D08623
|
Tramadol
| [5] 46 46, 70, 78, 226, 271 |
32 |
PDE2A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
33 |
PDE2A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
34 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
35 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
36 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
37 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
38 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
39 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
40 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
41 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
42 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
43 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
44 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
45 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
46 |
PDE1B
| [7] Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
47 |
PDE1B
| [7] Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
48 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08378
D08378
|
Pioglitazone
| [17] 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
49 |
PTGS1
| [5] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D07816
D07816
|
Diclofenac
| [5] 13 13, 34, 46, 78, 271 |
50 |
PTGS2
| [22] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D07816
D07816
|
Diclofenac
| [5] 13 13, 34, 46, 78, 271 |
51 |
SLC6A2
| [1] Synaptic vesicle cycle Synaptic vesicle cycle | D07448
D07448
|
Amitriptyline
| [4] 78 78, 97, 226, 299 |
52 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00326
D00326
|
Fluoxetine
| [6] 13 13, 17, 78, 86, 179, 206 |
53 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07448
D07448
|
Amitriptyline
| [4] 78 78, 97, 226, 299 |
54 |
SSTR1
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D07431
D07431
|
Somatostatin
| [2] 67 67, 78 |
55 |
SSTR2
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion | D07431
D07431
|
Somatostatin
| [2] 67 67, 78 |
56 |
SSTR3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D07431
D07431
|
Somatostatin
| [2] 67 67, 78 |
57 |
SSTR4
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D07431
D07431
|
Somatostatin
| [1] 78 78 |
58 |
SSTR5
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D07431
D07431
|
Somatostatin
| [2] 67 67, 78 |
59 |
THRA
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D07214
D07214
|
Tiratricol
| [2] 78 78, 139 |
60 |
THRA
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D08125
D08125
|
Levothyroxine
| [5] 19 19, 49, 78, 80, 222 |
61 |
THRA
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D08128
D08128
|
Liothyronine
| [4] 13 13, 78, 210, 212 |
62 |
THRB
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D07214
D07214
|
Tiratricol
| [2] 78 78, 139 |
63 |
THRB
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D08125
D08125
|
Levothyroxine
| [5] 19 19, 49, 78, 80, 222 |
64 |
THRB
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D08128
D08128
|
Liothyronine
| [4] 13 13, 78, 210, 212 |
65 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
66 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |